Traditional Chinese Herbs Found to Suppress Progression of Diabetes
|
By LabMedica International staff writers Posted on 28 Jan 2014 |

Image: According to a new study, the ability of Tianqi, a Chinese herbal medicine, to reduce the risk of developing diabetes, is similar to that of diabetes drugs, metformin and acarbose (Photo courtesy of the University of Chicago).
Traditional Chinese herbal medicines have the potential for slowing the progression from prediabetes to a clinical diabetes diagnosis, according to new research.
An individual who has developed raised blood sugar levels is diagnosed with prediabetes, but glucose levels have not yet been elevated to the point of developing type 2 diabetes. Individuals who are prediabetic are faced with an increased risk of developing type 2 diabetes as well as stroke and heart disease.
“With diabetes evolving into a serious public health burden worldwide, it is crucial to take steps to stem the flood of cases,” said one of the study’s authors, Chun-Su Yuan, MD, PhD, from the University of Chicago (IL, USA). “Patients often struggle to make the necessary lifestyle changes to control blood sugar levels, and current medications have limitations and can have adverse gastrointestinal side effects. Traditional Chinese herbs may offer a new option for managing blood sugar levels, either alone or in combination with other treatments.”
During the double-blind, randomized, placebo-controlled trial, 389 participants at 11 research sites in China were randomly assigned to take either a capsule containing a combination of 10 Chinese herbal medicines or a placebo. Study participants, for the duration of one year, took capsules of either the Chinese herb mixture, called Tianqi, or the placebo three times per day before meals. All participants received one month of lifestyle education at the beginning of the trial and met with nutritionists several times during the study. Study participants’ glucose tolerance was measured on a quarterly basis.
At the end of the trial, 36 participants in the Tianqi group and 56 in the placebo group had developed diabetes. The analysis found taking Tianqi reduced the risk of diabetes by 32.1% compared with the placebo, after adjusting for age and gender. The overall reduction in risk was similar to that found in studies of diabetes medications acarbose and metformin, and study participants reported few side effects from the Tianqi herbs. Tianqi includes various herbs that have been shown to lower blood glucose levels and increase regulation of blood glucose levels after meals.
“Few controlled clinical trials have examined traditional Chinese medicine’s impact on diabetes, and the findings from our study showed this approach can be very useful in slowing the disease’s progression,” said one of the study’s lead authors, Xiaolin Tong, MD, PhD, from Guang’anmen Hospital (Beijing, China). “More research is needed to evaluate the role Chinese herbal medicine can play in preventing and controlling diabetes.”
The findings were published February 2014, in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism (JCEM).
Related Links:
University of Chicago
Guang’anmen Hospital
An individual who has developed raised blood sugar levels is diagnosed with prediabetes, but glucose levels have not yet been elevated to the point of developing type 2 diabetes. Individuals who are prediabetic are faced with an increased risk of developing type 2 diabetes as well as stroke and heart disease.
“With diabetes evolving into a serious public health burden worldwide, it is crucial to take steps to stem the flood of cases,” said one of the study’s authors, Chun-Su Yuan, MD, PhD, from the University of Chicago (IL, USA). “Patients often struggle to make the necessary lifestyle changes to control blood sugar levels, and current medications have limitations and can have adverse gastrointestinal side effects. Traditional Chinese herbs may offer a new option for managing blood sugar levels, either alone or in combination with other treatments.”
During the double-blind, randomized, placebo-controlled trial, 389 participants at 11 research sites in China were randomly assigned to take either a capsule containing a combination of 10 Chinese herbal medicines or a placebo. Study participants, for the duration of one year, took capsules of either the Chinese herb mixture, called Tianqi, or the placebo three times per day before meals. All participants received one month of lifestyle education at the beginning of the trial and met with nutritionists several times during the study. Study participants’ glucose tolerance was measured on a quarterly basis.
At the end of the trial, 36 participants in the Tianqi group and 56 in the placebo group had developed diabetes. The analysis found taking Tianqi reduced the risk of diabetes by 32.1% compared with the placebo, after adjusting for age and gender. The overall reduction in risk was similar to that found in studies of diabetes medications acarbose and metformin, and study participants reported few side effects from the Tianqi herbs. Tianqi includes various herbs that have been shown to lower blood glucose levels and increase regulation of blood glucose levels after meals.
“Few controlled clinical trials have examined traditional Chinese medicine’s impact on diabetes, and the findings from our study showed this approach can be very useful in slowing the disease’s progression,” said one of the study’s lead authors, Xiaolin Tong, MD, PhD, from Guang’anmen Hospital (Beijing, China). “More research is needed to evaluate the role Chinese herbal medicine can play in preventing and controlling diabetes.”
The findings were published February 2014, in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism (JCEM).
Related Links:
University of Chicago
Guang’anmen Hospital
Latest BioResearch News
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
- Telomere Length Abnormalities Linked to Lymphoma Development
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read more
Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
Adjuvant therapy decisions after curative surgery for colon cancer remain difficult, as conventional clinicopathologic factors often fail to capture residual disease risk. Liquid biopsy approaches that... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read more
FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
Clinical laboratories play a central role in guiding immunotherapy by reporting programmed death ligand-1 (PD‑L1) status across multiple solid tumors. Many sites are standardizing this work on fully automated... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








